Insight
Podcast: How 2023 will shape the US Biosimilar space for 2024 and beyond
AmerisourceBergen
January 2024Insight
Gauge the impact: What does the striking down of a federal copay accumulator regulation mean for patients and copay programs?
AmerisourceBergen
October 2023Insight
Valuing potential cures: An examination of ICER’s approach to assessing high-impact single and short-term therapies
AmerisourceBergen
October 2023Insight
First 10 drugs for Medicare price negotiation announced under IRA
Corey Ford, MHA
August 2023Insight
HTA Quarterly | Fall 2023
Insight
Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties
AmerisourceBergen
August 2023Insight
The cures conundrum: The importance of getting value assessment right for transformational therapies
AmerisourceBergen
August 2023AmerisourceBergen
August 2023Insight
Empower your people and brand with biopharma learning solutions
AmerisourceBergen
June 2023Insight
On-demand webinar: The EU JCA process: Opportunities and challenges in bringing innovative medicines to patients in Europe
Insight
Reimbursement considerations for home infusions
Insight
Copay accumulator adjustment programs significantly increase patient financial burden
Insight
Issue Brief: Assessing the impact of formulary exclusion on healthcare costs and outcomes for patients on therapy for certain chronic conditions
Insight
Recap Asembia 2023: Our impactful contributions to the premier specialty pharmacy conference
AmerisourceBergen
May 2023Insight
Recap AMCP 2023: Our thought leadership in action
Insight
New pan-EU HTA: How can biopharma navigate the joint clinical assessment?
AmerisourceBergen
January 2023
.jpg?h=320&w=540)
